A Novel Multidose Dry Powder Inhaler and Its Application in Patients with Asthma and COPD

Abstract

Patient and physician satisfaction with the maintenance inhaler device is an important factor in medication adherence and effectiveness in respiratory disorders. We look at inhaler preferences in asthma and chronic obstructive pulmonary disease (COPD) from both the patient's and physician’s perspectives, emphasizing the relative importance of device features and patient considerations in inhaler selection. Teva Pharmaceuticals developed the multidose dry powder inhaler (M-DDPI) to treat chronic respiratory diseases. It is a metered-dose dry powder inhaler device intended to seem like a standard pressured metered-dose inhaler, but its internal geometry is somewhat distinctive. Inhalation treatment permits medication delivered directly to the airways. Inhalation devices serve a vital role in the therapy of obstructive lung illnesses such as asthma and COPD. The purpose of this research is to see how M-DDPI achieves maximum bronchial deposition of the medicine; the device must provide a high percentage of small particles, be simple to operate, and supply continuous and exact dosages of the active ingredient in COPD and asthma patients. Patients with COPD and asthma who had been diagnosed and treated at the hospital were first recruited as research participants and split into two groups. The control group got oxygen therapy as part of their standard treatment, whereas the experimental group received M-DDPI therapy. Statistical analysis techniques such as the Mann-Whitney U test and chi-squared test were used to examine the effects. The data show that the efficacies of M-DDPI therapy for COPD and asthma for obstructive lung illnesses seem to be promising right now.